Bipolar disorder (BD) is a highly prevalent affective psychiatric condition that affects nearly 2% of the global population [1-5]. It is characterized by chronic mood swings fluctuating from mania or hypomania to depression, which often cause significant impairment both socially and occupationally. The manic or hypomanic component involves 3 days or more of persistently elevated mood, recklessness, grandiosity, decreased need for sleep, reduced ability to concentrate, and irritability [2,4,6-8]. The depressive component involves 2 weeks or more of persistently low mood, anhedonia, poor appetite and sleep, reduced ability to concentrate, agitation or motor slowness, and suicidal ideation [4,8]. There are 4 main types of BD that are differentiated by the type, frequency, and severity of the mood episodes. Bipolar I disorder requires at least one manic episode, whereas bipolar disorder type II (BD-II) is characterized by depressive and hypomanic episodes. Cyclothymic disorder involves the presence of depressive and hypomanic states that do not meet diagnostic criteria and last a minimum of 2 years. Lastly, BD with mixed features is characterized by depressive and elevated moods simultaneously [2,4]. Unlike other types of BD, individuals with BD-II tend to experience longer and more persistent depressive episodes, sometimes with residual depressive symptoms, which are further exacerbated by the negative consequences of their hypomanic episodes [8].

Misdiagnosis and delayed treatment are common for individuals with BD, which can result in serious and sometimes irreversible outcomes. These outcomes can include more frequent and severe mood episodes, intellectual disability, loss of independence, and loss of ability to function [2,4,6,7,9-12]. Although mood-stabilizing medication remains the first line of treatment for BD, the beneficial effects of psychosocial treatments, particularly cognitive behavioral therapy (CBT), are now widely recognized [13]. Furthermore, the use of psychotherapy for the management of BD-II has evolved significantly over the past few decades [8]. CBT targets negative or dysfunctional thought patterns and behaviors through cognitive and behavioral restructuring techniques. These techniques aim to help the individual develop healthier or more balanced thought patterns (cognitive restructuration), which can then be applied in day-to-day life (behavioral restructuration). This can help with reducing psychiatric symptomatology and decreasing depressive episode duration along with increasing euthymic periods and improving global functioning and quality of life [14-20]. Furthermore, CBT specific for BD-II often includes techniques to practice acceptance, recognize warning signs of an upcoming mood episode, recognize potentially triggering stimuli, and develop an action plan with helpful steps and considerations to follow before, during, and after a mood episode [8,14,16,17,19,21,22].

However, several barriers prevent the broader uptake of CBT and other in-person psychotherapy options, including high costs, low availability, long waitlists, stigma against psychiatric interventions, and geographical and physical limitations [11]. Thus, web-based adaptations of traditional in-person CBT (e-CBT) have become promising alternatives due to their lowered cost, time effectiveness, flexibility, privacy, and convenience [14,23-25]. Additionally, e-CBT has been shown to increase help-seeking behaviors among patients and to have similar effectiveness at reducing psychiatric symptomatology as in-person CBT [11,14,26-28]. e-CBT programs often include weekly assignments for the participants and may be either fully self-guided or guided with asynchronous support from an assigned therapist [14]. Despite these benefits over in-person CBT, e-CBT options specific to BD remain significantly understudied and underdeveloped, and very few e-CBT programs have focused on BD-II [15-19,29].

To supplement this gap in the literature and guide clinical practice, this will be an open-label randomized controlled trial studying the effectiveness of a novel e-CBT program specific for BD-II in addition to treatment as usual (TAU; e-CBT + TAU). This program will be developed with the help of individuals with lived experience of BD-II to ensure applicability and accuracy. Thus, the primary objective of this study will be to determine the changes in BD symptomatology (hypomanic and depressive symptoms) of participants receiving e-CBT + TAU compared to participants receiving only TAU. Based on the evidence comparing e-CBT specific for BD to psychoeducation, attention controls, and TAU [16,17,19], this study hypothesizes that adding this e-CBT program to TAU will result in better symptom management than TAU by itself. The secondary objective will be to assess the effects of this e-CBT program on quality of life and resilience. The tertiary objective will involve gathering user feedback using a posttreatment survey to support the continuous improvement and optimization of the proposed program.

The literature comparing the efficacy of e-CBT specific for BD to psychoeducation, attention controls, and TAU has shown that e-CBT specific for BD is effective at reducing BD symptomatology (depression and mania or hypomania symptoms) and improving quality of life [16,17,19]. Thus, this study hypothesizes that adding this e-CBT program to TAU will result in better symptom management (reduction of BD symptomatology and improvement of quality of life) than TAU by itself. The study received notice of funding acceptance through the Queen’s University Department of Psychiatry Internal grant in December 2019. Participant recruitment will begin in February 2023 using targeted advertisements and physician referrals (see Methods). Complete data collection and analysis from all phases are expected to conclude by December 2024. All procedures and outcomes have been and will be reported using the CONSORT (Consolidated Standards of Reporting Trials) and TIDieR (Template for Intervention Description and Replication) Report Guidelines [42]. This study has been registered through the ClinicalTrials.gov system (NCT04664257).

This is a protocol for an RCT that aims to establish the first e-CBT program for the management of BD-II with residual depressive symptoms. This program will cover helpful coping techniques to increase euthymic periods and improve global functioning by applying the widely validated principles of CBT [14-20]. Based on literature evidence, previous clinical trials conducted by NA, and the use of a validated therapy approach, this study hypothesizes that this novel e-CBT program will have similar effectiveness as face-to-face CBT for the management of BD-II with residual depressive symptoms [14,33,35-37].

The management of BD-II involves the use of mood-stabilizing medications and psychosocial interventions [13]. Thus, given the proven efficacy of CBT for a variety of psychiatric conditions, the development of CBT for the management of BD-II has become a growing area of research [8]. CBT for BD-II usually involves face-to-face sessions with a therapist and covers techniques to practice acceptance, recognize warning signs of an upcoming mood episode, recognize potentially triggering stimuli, and develop an action plan [14-20]. However, access to in-person CBT faces significant barriers, including high costs, low availability, long waitlists, stigma against psychiatric interventions, and geographical and physical limitations [11]. Also, despite advances in the development and validation of web-based adaptations of CBT for other psychiatric conditions [14,15,20], e-CBT options specific for the treatment of BD-II remain understudied [15-19]. This presents an important gap in the literature with potentially detrimental consequences for individuals with this condition.

The strengths of this novel e-CBT program and of this study include the use of a validated approach for the delivery of interactive, predesigned web-based modules with the asynchronous guidance of a therapist through the OPTT platform [14,33,35-37]. Also, by taking advantage of the web-based medium, this program has the potential to improve accessibility, cost, time effectiveness, flexibility, privacy, and convenience. For instance, previous studies have shown that asynchronous psychotherapy, through the use of predesigned web-based modules, allows therapists to deliver care to 3-4 patients in the same time as a traditional hour-long in-person session [14,33,35-37]. Furthermore, using the OPTT platform, this study will be able to reliably collect user analytics, which allows for the improvement and continuous optimization of e-CBT program delivery. Additionally, by comparing this proposed program to a validated therapeutic approach (face-to-face CBT for the management of BD-II) [14-20], the design of this study should provide helpful evidence for the validation of e-CBT for the management of BD-II with residual depressive symptoms.

Moreover, the knowledge dissemination plan for this study includes the publication of the findings in a peer-reviewed academic journal. The findings will also be presented broadly through academic meetings and conferences. Thus, this plan ensures the commitment to continuing education in the relevant research areas. Also, collaboration with the Canadian enterprise OPTT Inc. will enhance the dissemination and application of knowledge. Additionally, by providing this service to clinicians, the care capacity for accessible, affordable, and high-quality mental health care could be more rapidly scaled across Canada.

Though this study has some potential limitations that mainly stem from the web-based mode of delivery of this program, the main limiting factor is that participants would need a reliable internet connection and sufficient technology literacy to participate. In turn, this could introduce biases in participant demographic characteristics. To account for this, this study will analyze demographic factors through multiple sample t tests to identify the impact of these factors on treatment outcomes. Additionally, the design of this study is limited by the lack of therapist and client blinding. However, due to the delivery mode and design of the program, it is not possible to conceal client allocation. Furthermore, web-based psychotherapy is often characterized by significant dropout rates, with some studies reporting a dropout rate of up to 30% by the end of the treatment or TAU phases [14,33,35,37,40]. Hence, this study is intentionally oversampling to account for this potential high dropout rate without compromising the statistical power of this study.

In conclusion, this study recognizes the significant potential of web-based psychotherapy as a tool that can lower costs and increase capacity and accessibility in mental health care, as well as the lack of available web-based psychotherapy options for individuals with BD-II. Therefore, the results of this study aim to fill an important gap in the literature through the development, implementation, and validation of a novel e-CBT program for the management of BD-II with residual depressive symptoms. Additionally, these results aim to inform clinical practice and health care policy to support the widespread implementation of web-based psychotherapy, with potential benefits to the care capacity and performance of the health care system.